Drug intelligence / Profile preview

decitabine + venetoclax + blinatumomab

Development stage: Unknown
Lead developer: Eisai
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination involves **decitabine**, a hypomethylating agent used to treat myelodysplastic syndromes and certain leukemias; **venetoclax**, a BCL-2 inhibitor used in the treatment of various hematological malignancies; and **blinatumomab**, a bispecific monoclonal antibody targeting CD19 and CD3, used primarily in acute lymphoblastic leukemia (ALL). The combination is being studied for its potential to improve progression-free survival in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia following allogeneic stem cell transplantation.

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)BCL-2 (BCL-2 family)CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on decitabine + venetoclax + blinatumomab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on decitabine + venetoclax + blinatumomab.

Explore the full profile